Table 5.

Odds Ratios for Treated LDL-C <100 mg/dL Among Adults With Heterozygous FH Taking LDL-Lowering Medications (n=1084)

Characteristic	LDL-C ≥100 mg/dL (N=816)	LDL-C <100 mg/dL (N=268)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)*
Age at enrollment, years†	55 (42–65)	60 (49–67)	1.23 (1.13–1.35)	1.21 (1.01–1.45)
Male	325 (40.1%)	136 (50.7%)	1.49 (1.32–1.69)	1.24 (0.90–1.70)
Coronary heart disease	273 (33.5%)	122 (45.5%)	1.55 (1.21–1.98)	1.27 (0.91–1.79)
Family history of premature MI	365 (61.9%)	129 (66.5%)	1.20 (0.77–1.88)	1.89 (0.90–3.96)
Diabetes mellitus	93 (11.5%)	42 (15.8%)	1.24 (0.63–2.43)	1.10 (0.38–3.22)
Untreated LDL-C, mg/dL†	245 (215–300)	225 (197–270)	0.95 (0.92–0.98)	0.93 (0.90–0.97)
Confirmed FH mutation	32 (3.9%)	3 (1.1%)	0.29 (0.06–1.38)	0.17 (0.04–0.74)
High-intensity statin‡	374 (45.8%)	162 (60.4%)	4.23 (2.33–7.68)	4.83 (2.24–10.45)
Low- or moderate intensity statin‡	333 (40.8%)	90 (33.6%)	2.37 (1.31–4.29)	2.41 (0.93–6.20)
>1 lipid-lowering medication	407 (49.9%)	171 (63.8%)	1.84 (1.46–2.32)	1.86 (1.47–2.36)

CHD indicates coronary heart disease; CI, confidence interval; FH, familial hypercholesterolemia; IQR, interquartile ratio; LDL, low-density lipoprotein; and LDL-C, LDL cholesterol; MI, myocardial infarction; and OR, odds ratio.

^*Adjusted for age, sex, untreated LDL-C, CHD, statin use, and use of >1 LDL-lowering medication.

^†Median (IQR) shown.

^‡OR compared with no statin use.